APA (7th ed.) Citation

WC, W., S, A., SK, B., GM, C., KU, E., AG, J., . . . PS, P. (2023). Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Naïve Patients. Kidney medicine, 5(7), 100666. https://doi.org/10.1016/j.xkme.2023.100666

Chicago Style (17th ed.) Citation

WC, Winkelmayer, et al. "Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Naïve Patients." Kidney Medicine 5, no. 7 (2023): 100666. https://doi.org/10.1016/j.xkme.2023.100666.

MLA (9th ed.) Citation

WC, Winkelmayer, et al. "Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO2TECT Randomized Clinical Trial of ESA-Naïve Patients." Kidney Medicine, vol. 5, no. 7, 2023, p. 100666, https://doi.org/10.1016/j.xkme.2023.100666.